DE60330952D1 - N- i(2S)-4-(3,4-DIFLUOROBENZYL)MORPHOLIN-2-YL METHYL -2- 3-i(METHYLSULPHONYL)AMINO PHENYL ACETAMID ALS CCR3 ANTAGONIST FÜR DIE BEHANDLUNG VON ENTZÜNDLICHEN ERKRANKUNGEN - Google Patents

N- i(2S)-4-(3,4-DIFLUOROBENZYL)MORPHOLIN-2-YL METHYL -2- 3-i(METHYLSULPHONYL)AMINO PHENYL ACETAMID ALS CCR3 ANTAGONIST FÜR DIE BEHANDLUNG VON ENTZÜNDLICHEN ERKRANKUNGEN

Info

Publication number
DE60330952D1
DE60330952D1 DE60330952T DE60330952T DE60330952D1 DE 60330952 D1 DE60330952 D1 DE 60330952D1 DE 60330952 T DE60330952 T DE 60330952T DE 60330952 T DE60330952 T DE 60330952T DE 60330952 D1 DE60330952 D1 DE 60330952D1
Authority
DE
Germany
Prior art keywords
methylsulphonyl
difluorobenzyl
morpholin
methyl
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60330952T
Other languages
German (de)
English (en)
Inventor
Rachael Ann Ancliff
Caroline Mary Cook
Colin David Eldred
Paul Martin Gore
Lee Andrew Harrison
Martin Alistair Hayes
Simon Teanby Hodgson
Duncan Bruce Judd
Suzanne Elaine Keeling
Xiao Qing Lewell
Gail Mills
Graeme Michael Robertson
Stephen Swanson
Andrew John Walker
Mark Wilkinson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of DE60330952D1 publication Critical patent/DE60330952D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
DE60330952T 2002-03-28 2003-03-27 N- i(2S)-4-(3,4-DIFLUOROBENZYL)MORPHOLIN-2-YL METHYL -2- 3-i(METHYLSULPHONYL)AMINO PHENYL ACETAMID ALS CCR3 ANTAGONIST FÜR DIE BEHANDLUNG VON ENTZÜNDLICHEN ERKRANKUNGEN Expired - Lifetime DE60330952D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0207449.0A GB0207449D0 (en) 2002-03-28 2002-03-28 Novel compounds
PCT/EP2003/003339 WO2003082291A1 (en) 2002-03-28 2003-03-27 N-{´ (2s) -4- (3, 4-difluorobenzyl) morpholin-2yl!methyl} -2-{3-' (methylsulphonyl) amino! phenyl}acetamide as ccr3 antagonist for the treatment of inflammatory conditions

Publications (1)

Publication Number Publication Date
DE60330952D1 true DE60330952D1 (de) 2010-03-04

Family

ID=9933998

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60330952T Expired - Lifetime DE60330952D1 (de) 2002-03-28 2003-03-27 N- i(2S)-4-(3,4-DIFLUOROBENZYL)MORPHOLIN-2-YL METHYL -2- 3-i(METHYLSULPHONYL)AMINO PHENYL ACETAMID ALS CCR3 ANTAGONIST FÜR DIE BEHANDLUNG VON ENTZÜNDLICHEN ERKRANKUNGEN

Country Status (22)

Country Link
US (1) US20060058299A1 (enExample)
EP (1) EP1487453B1 (enExample)
JP (1) JP4490110B2 (enExample)
KR (1) KR20040095347A (enExample)
CN (1) CN1642553A (enExample)
AR (1) AR039177A1 (enExample)
AT (1) ATE454892T1 (enExample)
AU (1) AU2003216905A1 (enExample)
BR (1) BR0308719A (enExample)
CA (1) CA2479910A1 (enExample)
DE (1) DE60330952D1 (enExample)
ES (1) ES2339436T3 (enExample)
GB (1) GB0207449D0 (enExample)
IL (1) IL163648A0 (enExample)
IS (1) IS7415A (enExample)
MX (1) MXPA04009458A (enExample)
NO (1) NO20044098L (enExample)
PL (1) PL372930A1 (enExample)
RU (1) RU2004126145A (enExample)
TW (1) TW200400823A (enExample)
WO (1) WO2003082291A1 (enExample)
ZA (1) ZA200406990B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004028530A1 (en) 2002-09-26 2004-04-08 Bristol-Myers Squibb Company N-substituted heterocyclic amines as modulators of chemokine receptor activity
JP2009501792A (ja) * 2005-07-21 2009-01-22 アストラゼネカ・アクチエボラーグ ケモカイン受容体のモジュレーターとしてのｎ−ベンジル−モルホリン誘導体
HUP0500877A2 (en) * 2005-09-22 2007-05-29 Sanofi Aventis Amide derivatives as ccr3 receptor ligands, process for producing them, pharmaceutical compositions containing them and their use and intermediates
HUP0500886A2 (en) * 2005-09-23 2007-05-29 Sanofi Aventis Amide derivatives as ccr3 receptor ligands, process for producing them, pharmaceutical compositions containing them and their use
WO2007034252A1 (en) * 2005-09-22 2007-03-29 Sanofi-Aventis Amino-alkyl-amide derivatives as ccr3 receptor liquids
HUP0800478A2 (en) * 2008-07-31 2010-03-01 Sanofi Aventis Substituted pyrrolidinyl-[1,3]thiazolo[4,5-b]pyridin derivatives as ccr3 receptor ligands
WO2013079696A1 (en) * 2011-12-01 2013-06-06 Glaxo Group Limited Methods of treatment and prevention of eye diseases

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS562929A (en) * 1979-06-21 1981-01-13 Sumitomo Chem Co Ltd Preparation of optically active cyclopentenolone
US4870074A (en) * 1986-04-30 1989-09-26 Dainippon Pharmaceutical Co., Ltd. Substituted benzamide derivatives, for enhancing gastrointestinal motility
JPH01117882A (ja) * 1987-10-30 1989-05-10 Dainippon Pharmaceut Co Ltd 複素環式カルボン酸アミド誘導体
JPH03291274A (ja) * 1990-04-09 1991-12-20 Yoshitomi Pharmaceut Ind Ltd アミノアルキルモルホリン誘導体の製造法
JPH04270272A (ja) * 1991-02-25 1992-09-25 Yoshitomi Pharmaceut Ind Ltd アミノアルキルモルホリン誘導体の製造法
TW223629B (enExample) * 1992-03-06 1994-05-11 Hoffmann La Roche
US5219856A (en) * 1992-04-06 1993-06-15 E. I. Du Pont De Nemours And Company Angiotensin-II receptor blocking, heterocycle substituted imidazoles
US6031097A (en) * 1997-10-27 2000-02-29 Neurogen Corporation 1-(N-(arylalkylaminoalkyl) aminoisoquinolines; a new class of dopamine receptor subtype specific ligands
AU2056800A (en) * 1998-12-18 2000-07-03 Du Pont Pharmaceuticals Company Heterocyclic piperidines as modulators of chemokine receptor activity
ATE254620T1 (de) * 1999-09-14 2003-12-15 Aventis Pharma Inc Unsubstituierte ethyl- und propylderivate von phenoxythienoisoxazolen als d4 antagonisten
CZ20031195A3 (cs) * 2000-09-29 2003-09-17 Glaxo Group Limited Morfolinacetamidové deriváty
ES2275729T3 (es) * 2000-09-29 2007-06-16 Glaxo Group Limited Compuestos utiles en el tratamiento de enfermedades inflamatorias.

Also Published As

Publication number Publication date
CN1642553A (zh) 2005-07-20
RU2004126145A (ru) 2005-06-27
CA2479910A1 (en) 2003-10-09
KR20040095347A (ko) 2004-11-12
ATE454892T1 (de) 2010-01-15
NO20044098L (no) 2004-10-04
IS7415A (is) 2004-08-19
JP4490110B2 (ja) 2010-06-23
IL163648A0 (en) 2005-12-18
GB0207449D0 (en) 2002-05-08
PL372930A1 (en) 2005-08-08
ZA200406990B (en) 2005-11-08
BR0308719A (pt) 2005-01-04
ES2339436T3 (es) 2010-05-20
AU2003216905A1 (en) 2003-10-13
JP2005525390A (ja) 2005-08-25
EP1487453A1 (en) 2004-12-22
EP1487453B1 (en) 2010-01-13
AR039177A1 (es) 2005-02-09
US20060058299A1 (en) 2006-03-16
WO2003082291A1 (en) 2003-10-09
TW200400823A (en) 2004-01-16
MXPA04009458A (es) 2005-07-27

Similar Documents

Publication Publication Date Title
DE60316116D1 (de) Amide von aminoalkylsubstituierten azetidinen, pyrrolidinen, piperidinen und azepanen
ATE361279T1 (de) N-[phenyl(piperidin-2-yl)methyl]benzamidderivat , verfahren zu ihrer herstellung und ihre therapeutische anwendung
EP1641748A4 (en) N-ALKYLPHENYLCARBOXAMIDE BETA SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER DISEASE
ATE345331T1 (de) Verbindungen verwendbar für die behandlung von entzündungskrankheiten
EP1513403A4 (en) USE OF CARDIOTONIC GLUCOSIDES FOR THE TREATMENT OF MUCOVICIDOSIS AND OTHER IL-8 DEPENDENT DISORDERS
NO20064418L (no) Nye amido-substituerte hydroksy-6-fenylfenantridiner
DK1651615T3 (da) Pyridazinyl-piperaziner og anvendelse deraf som histamin-H3-receptorligander
DE60218493D1 (de) Substituierte 7-aza-ä2.2.1übicycloheptane für die behandlung von krankheiten
ATE535236T1 (de) Therapeutische strategien für die prävention und behandlung der alzheimer-krankheit
EP1643986A4 (en) PHENYL ACARBOXYLATE BETA SECRETASE INHIBITORS FOR THE TREATMENT OF MORBUS ALZHEIMER
ATE418554T1 (de) 1-acyl-pyrrolidin-derivate für die behandlung von viralen infektionen
ATE299139T1 (de) Ccr5 antagonisten verwendbar für die behandlung von aids
DE60231107D1 (de) Tetrahydro-pyrazinoä1,2-aüindole für die behandlung von krankheiten des zentralnervensystems
BRPI0417858A (pt) composto, composição farmacêutica, e, uso de uma composição farmacêutica
DE60330952D1 (de) N- i(2S)-4-(3,4-DIFLUOROBENZYL)MORPHOLIN-2-YL METHYL -2- 3-i(METHYLSULPHONYL)AMINO PHENYL ACETAMID ALS CCR3 ANTAGONIST FÜR DIE BEHANDLUNG VON ENTZÜNDLICHEN ERKRANKUNGEN
EA200400280A1 (ru) Новые неочищенные и кристаллические формы гидрохлорида лерканидипина
ATE381263T1 (de) Fungizide zusammensetzungen, die n-(alpha-cyano-2-thenyl)-4-ethyl-2-ethylamino-5 thiazolcarboxamide enthalten
NO20050740L (no) Ny fremgangsmate for syntesen av (7-metoksy-1-naftyl)acetonitril og anvendelse i syntesen av agomelatin
ATE514697T1 (de) 7-ä4-ä2-(2,6-dichloro-4- methylphenoxy)ethoxyüphenylü-3,9- diazabicycloä3.3.1ünon-6-ene-6-carbonsäure- cyclopropyl-(2,3-dimethylbenzyl)amid als renin- hemmer für die behandlung von bluthochdruck
DE60307086D1 (de) Zusammensetzng auf diclofenac-basis für die topische behandlung von erkrankungen des oropharynx
ATE420860T1 (de) N-substituierte amide als nk1 rezeptor antagonisten
UY28145A1 (es) Nuevos compuestos farmaceuticos
HK1071699A (en) N-[(2s)-4-(3,4-difluorobenzyl)morpholin-2-yl]methyl-2-3-[(methylsulphonyl)amino]phenyl acetamide as ccr3 antagonist for the treatment of inflammatory conditions
DE60110233D1 (de) Neue n-(2-phenyl-3-aminopropyl)naphtamide
BR0011330A (pt) 2-aril-1,2,4-triazina-3,5-di(ti)onas substituìdas

Legal Events

Date Code Title Description
8364 No opposition during term of opposition